213 related articles for article (PubMed ID: 35665371)
21. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
[TBL] [Abstract][Full Text] [Related]
22. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
23. [WT1 peptide-based immunotherapy].
Sugiyama H
Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
[TBL] [Abstract][Full Text] [Related]
24. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
25. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
[TBL] [Abstract][Full Text] [Related]
26. Expression of the 11p13 Wilms' tumor gene, WT1, correlates with histologic category of Wilms' tumor.
Gerald WL; Gramling TS; Sens DA; Garvin AJ
Am J Pathol; 1992 May; 140(5):1031-7. PubMed ID: 1316081
[TBL] [Abstract][Full Text] [Related]
27. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
28. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
Rosenfeld C; Cheever MA; Gaiger A
Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.
Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S
Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161
[TBL] [Abstract][Full Text] [Related]
31. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.
Yokota C; Nakata J; Takano K; Nakajima H; Hayashibara H; Minagawa H; Chiba Y; Hirayama R; Kijima N; Kinoshita M; Hashii Y; Tsuboi A; Oka Y; Oji Y; Kumanogoh A; Sugiyama H; Kagawa N; Kishima H
Neurooncol Adv; 2021; 3(1):vdab091. PubMed ID: 34355173
[TBL] [Abstract][Full Text] [Related]
32. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for leukemia targeting the Wilms' tumor gene.
Yasukawa M
Leuk Lymphoma; 2001 Jul; 42(3):267-73. PubMed ID: 11699391
[TBL] [Abstract][Full Text] [Related]
34. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.
Luo P; Jing W; Yi K; Wu S; Zhou F
Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109
[TBL] [Abstract][Full Text] [Related]
35. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor gene WT1: its oncogenic function and clinical application.
Sugiyama H
Int J Hematol; 2001 Feb; 73(2):177-87. PubMed ID: 11372729
[TBL] [Abstract][Full Text] [Related]
37. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
38. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
39. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy.
Nagai H; Karube R
Cureus; 2023 Nov; 15(11):e49221. PubMed ID: 38143707
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]